



Tyrosol improves ovalbumin (OVA)-induced asthma in rat model through prevention of airway inflammation

Mustafa Cellat¹ · Müslüm Kuzu² · Cafer Tayer İşler³ · Muhammed Etyemez¹ · Nursel Dikmen⁴ · Ahmet Uyar⁵ · İshak Gökçek¹ · Erdinç Türk⁶ · Mehmet Güvenç¹

Received: 21 April 2021 / Accepted: 23 June 2021 / Published online: 21 July 2021

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021, corrected publication 2021

Abstract

Asthma is an inflammatory disease that affects many people around the world, especially persons at paediatric age group. The effectiveness of tyrosol, a natural phenolic compound, was examined in the asthma model induced by ovalbumin (OVA). For this purpose, four groups, each consisting of eight rats, were arranged. For 21 days, physiological saline solution was treated to the control group and OVA was treated to the groups of OVA, OVA + dexamethasone (Dexa) and OVA + tyrosol groups, intraperitoneally and through inhalation. Additionally, 0.25 mg/kg Dexa was treated to the OVA + Dexa group and 20 mg/kg tyrosol to the OVA + tyrosol group by oral gavage. Serum, blood, bronchoalveolar lavage fluid (BALF) and lung tissues of the rats were examined. It was observed that MDA level decreased, GSH level and GPx activity increased, and there was no change in CAT activity in lung tissues of the tyrosol treatment groups. It was also observed that NF- κ B, TNF- α , IL-4, IL-5, IL-13, IFN- γ and IgE levels decreased compared to the OVA group in lung tissue and serum samples except for serum NF- κ B and IL-4. However, no effect on IL-1 β level was observed. In addition, it was determined that tyrosol treatment increased the IL-10 level on both tissue samples. The results of the histopathological investigation of lung tissue showed that tyrosol significantly ameliorated OVA-induced histopathological lesions. Additionally, PAS staining showed that mucus hypersecretion was significantly reduced with the use of tyrosol. In addition, it was determined that the number of eosinophils decreased significantly in blood and BALF samples. The obtained results showed that tyrosol possessed antioxidant and anti-inflammatory features on OVA-induced rats and preserved tissue architecture.

Keywords Asthma · Tyrosol · Antioxidant · Anti-inflammatory · Anti-allergic

Introduction

Allergic asthma is as a complex inflammatory disease characterized by immune-mediated hypersensitivity reaction and chronic airway inflammation (Saikumar Jayalatha et al. 2021). Airflow limitation is seen common in patients with asthma, and its clinical symptoms include stertorous respiration, shortness of breath, chest tightness and cough. It has been reported that the incidence of asthma has increased greatly in the last decade and, if not treated on time, that it can be fatal, and that it affects more than 300 million individuals worldwide (Mattiuzzi and Lippi 2020; Stern et al. 2020; Innes Asher et al. 2020). Airway hyperresponsiveness (AHR) is one of the most prominent features of asthma. Hypersensitivity of the airways include various cytokines and mast cells and T cells in addition to inflammatory cells such as neutrophils and eosinophils (Regele 2000; Elaidy et al. 2018). Mast cells play important roles not only in

✉ Mustafa Cellat
mcellat@mku.edu.tr; mstcellat@hotmail.com

¹ Faculty of Veterinary Medicine, Department of Physiology, Hatay Mustafa Kemal University, 31060 Hatay, Turkey

² Faculty of Health Sciences, Department of Nutrition and Dietetics, Karabük University, Karabük, Turkey

³ Faculty of Veterinary Medicine, Department of Surgery, Hatay Mustafa Kemal University, Hatay, Turkey

⁴ Faculty of Medicine, Department of Chest Diseases, Hatay Mustafa Kemal University, Hatay, Turkey

⁵ Faculty of Veterinary Medicine, Department of Pathology, Hatay Mustafa Kemal University, Hatay, Turkey

⁶ Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, Hatay Mustafa Kemal University, Hatay, Turkey

inflammation and sudden allergic reactions, but also in the development of chronic airway inflammation and airway remodelling, and in the clinical symptoms of asthma (Chiappara et al. 2001; Russell and Brightling 2017). Asthma is a chronic inflammatory disorder of the airways with a change in the T helper (Th) 1/Th2 balance and an imbalance in the ratio between regulatory T cells (Chan et al. 2016). It has been reported that while Th2 cell cytokines cause inflammatory responses in the asthmatic airways, Th1 cells can inhibit the development of Th2 cells and reduce the asthma response caused by Th2 (Yang et al. 2019). Currently, the protocols used in the treatment of asthma include inhaled and oral corticoid steroids and short-acting beta agonists, and besides their serious side effects, they show only symptomatic effects (Kaplan et al. 2020). Asthmatic patients most frequently use inhaled corticosteroids with low systemic bioavailability, thus greatly reducing the risk of immunosuppression and infection (Irwin and Richardson 2006). However, corticosteroids have been reported to be the most effective nonspecific anti-inflammatory drugs used extensively in the treatment of asthma, but it has been stated that they cause systemic immunosuppression and that this leads to an increase in the possibility of infection (Migliorati et al. 1994). For this reason, the issue of determining safe and effective alternatives for the treatment of this disease has become attractive for researchers and it has been stated that especially natural prospective drugs with minimal side effects have come to the fore (Ezz-Eldin et al. 2020).

Found mainly in olive oil and white wine and having many known biological and physiological activities, tyrosol, 2-(4-hydroxyphenyl)-ethanol, is a phenolic compound (Rodríguez-Morató et al. 2016). Together with hydroxytyrosol, it is one of the main phenolic compounds of olive oil (Fitó et al. 2000). In some studies conducted to determine the biological activities of tyrosol, it has been reported that it has antidiabetic effect by regulating carbohydrate metabolism (Chandramohan et al. 2015), and that it has neuroprotective effect in cerebral ischaemia in rats thanks to its antioxidant feature (Bu et al. 2007). Besides, anti-depressant, anti-stress, anti-inflammatory and anti-apoptotic effects of tyrosol have also been reported (Tuck and Hayball 2002; Atochin et al. 2016; Plotnikov and Plotnikova 2021). The protective efficacy of tyrosol, which has been reported to have many biological activities until today, in an experimental animal asthma model was investigated in the study. For this purpose, an asthma model was created in rats with ovalbumin (OVA), which is universally used as a protein allergen in asthma models due to its effectiveness on immune response changes of T cells (Sun et al. 2010). On the other hand, the protective effects of tyrosol were figured out in the light of the analysis of oxidation and inflammation markers and histopathological findings. The obtained findings were compared with dexamethasone (Dexa), as the standard reference.

Material and method

Animals used in the experiment

In the experiment, 32 Wistar albino rats, which are 10 weeks old and weighing 220–250 g, were used. The animals used in the experiment were obtained from Hatay Mustafa Kemal University Experimental Researches Application and Research Centre. The working environment was executed where rats were in a daily cycle and in accordance with the conditions of the care and use of laboratory animals (12 h of light-12 h of dark and at 21 ± 1 °C).

Chemical and reagent kits

Interleukin (IL)-1 β , IL-4, IL-5, IL-10, IL-13, tumour necrosis factor alpha (TNF- α), interferon gamma (IFN- γ), nuclear factor kappa B (NF- κ B) and immunoglobulin E (IgE) enzyme-linked immunosorbent assay (ELISA) kits used in the study were purchased from Bioassay Technology Laboratory, China. OVA (grade II), aluminium hydroxide (Al(OH)₃) and tyrosol were bought from Sigma-Aldrich Chemical Co., USA. Decort (Deva) commercial preparate was used as dexamethasone. Other chemicals and solutions used in the study were purchased in analytical purity from Sigma-Aldrich Chemical Co., USA.

Experimental protocol

Study groups consisted of four groups in total: group 1 (control group), group 2 (OVA), group 3 (asthma + Dexa 0.25 mg/kg) and group 4 (asthma + tyrosol 20 mg/kg). Establishing an experimental allergic asthma model and usage doses of dexamethasone were determined according to the literature (Boskabady et al. 2019). The dosage of tyrosol was made in accordance with the study of Güvenç et al. (2019). The rats in the control group underwent the practices of 1 ml physiological saline solution by oral gavage method once a day from the 1st to the 22nd day of the study; physiological saline solution intraperitoneally with a volume of 1 ml once a day on the 1st, 2nd and 3rd day; and physiological saline solution as an aerosol with the help of a nebulizer (Omron) in a closed box with a dimensions of 35 cm $\times$ 25 cm $\times$ 15 cm on the 6th, 9th, 12th, 15th, 18th and 21st days for a total of 6 days. To create sensitivity in rats in group 2, group 3 and group 4, 1 ml allergen suspension containing 1 mg ovalbumin + 100 mg aluminium hydroxide in physiological saline solution was administered intraperitoneally on the 1st, 2nd and 3rd days of the study, and 1% ovalbumin solution in physiological saline solution was administered with the help of a nebulizer (Omron) on the 6th, 9th, 12th, 15th, 18th and 21st

days, once a day for 20 min, as aerosol. In addition, the rats in group 2 were administered 1 ml of physiological saline solution by oral gavage method once a day from the 1st to the 22nd day, and the rats in group 3 were administered Dexamethasone once a day from the 1st to the 22nd day of the study in 1 ml physiological saline solution by oral gavage method and at a dose of 0.25 mg/kg. In group 4, tyrosol was administered once a day from the 1st to the 22nd day of the study in 1 ml physiological saline solution at a dose of 20 mg/kg by oral gavage method. It has been reported in the literature that this dose of tyrosol does not have a toxic effect (Chandramohan et al. 2015). All applications within the scope of the experiment were conducted within the framework of the Hatay Mustafa Kemal University Animal Experiments Local Ethics Committee's permit numbered 2019/09–3.

Bronchoalveolar lavage fluid output

On the 22nd day of the experiment, rats were anaesthetized (xylazine 10 mg/kg + ketamine 60 mg/kg) and tracheostomy was performed by using a 12-gauge cannula (2 mm inner diameter). After tracheostomy, heparinized saline (0.1 ml) was injected intravenously through the femoral vein to prevent blood clotting. In the cases when excessive bronchial secretions were found, they were discharged by using a small polyethylene tube. The lungs were washed three times (3 × 5 ml) through a cannulated tracheal tube with 5.0 ml of physiological saline solution. Bronchoalveolar lavage fluid (BALF) was collected (approximately 11–12 ml/rat) and centrifuged at 1500 rpm, at 4 °C for 10 min. It was stored at – 80 °C until analysis was done.

Determination of total and differential leukocyte count in BALF

To figure out the total and differential leukocyte count, the cell pellet was resuspended in 1 ml of physiological saline solution. Froti prepared from BALF fluid was stained with Giemsa stain, and the percentage of leukocytes was determined.

Taking and analysing blood samples and detection of blood parameters

After the BALF and blood were collected, the anaesthetized rats were decapitated. Haemogram parameters were measured in the automatic blood count device of brand Mindray 2800 BC on fresh blood samples taken into blood tubes with EDTA. In addition, smears were prepared from these fresh blood samples and leukocyte percentages were determined by the Giemsa staining method. Serums were prepared from blood samples taken into serum tubes and stored at – 80 °C

for the analysis of oxidative damage and inflammation parameters.

Determination of lipid peroxidation, glutathione level and catalase and glutathione peroxidase activities

Samples taken from lung tissues were homogenized with 1.15% KCl at a ratio of 1:10, and MDA analysis was performed in half of the homogenate. The other half of it was centrifuged at 5000 g for 1 h (at + 4 °C), its supernatants were separated and their glutathione (GSH), glutathione peroxidase (GPx) and catalase (CAT) analyses were performed. In the study, the MDA level was determined according to the method of Ohkawa et al. (1979). The method of Beutler et al. (1963) was used to determine the reduced GSH level. MDA and GSH levels are given in nmol/ml. CAT enzyme activity was determined according to the method of Aebi (1984), and GPx activity was determined according to the method of Beutler (1975). Protein analyses in the homogenate and supernatant were performed according to the method of Lowry et al. (1951).

Preparation of lung tissue homogenate for ELISA analysis

After BALF collection, the left lungs were harvested for assessment ELISA analyses. The lungs were homogenized using a tissue homogenizer (BioSpec Products, Racine, WI) in 1 ml lysis buffer containing 0.5% Triton X-100, 150 mM NaCl, 15 mM Tris, 1 mM CaCl₂ and 1 mM MgCl₂ (pH 7.4). Homogenates were then centrifuged at 10,000 × g for 10 min. Supernatants were stored at – 80 °C for later assessment (Whitehead et al. 2003).

Determination of inflammation and allergic reaction markers

Inflammation markers in lung tissue and serum samples were determined through ELISA by using commercial kits. The measurements in determining the amounts of IL-1β, IL-4, IL-5, IL-10, IL-13, TNF-α, IFN-γ and NF-κB, which are the inflammation markers, and IgE protein, which is an allergic reaction marker, were made by using an ELISA plate reader.

Histopathological evaluation

At the end of the experiment, all rats were sacrificed for histological examination. The lobe of the left lung tissue was removed and fixed in 10% neutral buffered formalin for 48 h the tissue. The lung tissue samples were blocked in paraffin after they were dehydrated by passing through

an ascending alcohol series and became transparent by passing through a series of xylene. Serial sections of 5 µm thick were taken from these paraffin blocks by microtome (Leica RM 2135) and then stained with haematoxylin and eosin (H&E) and periodic acid-Schiff (PAS). The slides were examined (Olympus CX21, Olympus Corporation, Tokyo, Japan) and photographed (Olympus DP12) using a light microscope. To determine the severity of inflammatory cell infiltration, peribronchial cell counts were performed blindly based on a 5-point scoring system as previously described (Myou et al. 2003). Briefly, the scoring system was as follows: 0, no cells; 1, a few cells; 2, a ring of cells (1 cell layer deep); 3, a ring of cells (2–4 cells deep); and 4, a ring of cells (> 4 cells deep). To determine the extent of mucus production, goblet cell hyperplasia in the airway epithelium was quantified blindly by using a 5-point grading system described by Tanaka and colleagues (Tanaka et al. 2001). The adopted grading system for mucus production scores (MPS) was as follows: 0, < 0.5% PAS-positive cells; 1, < 25%; 2, 25–50%; 3, 50–75%; and 4, > 75%. Scoring of inflammatory cells and goblet cells was performed in at least five different fields for each lung section. Additionally, the lung injury scores were based on the following categories: inflammation, congestion, haemorrhage and thickened interalveolar septa according to the previously described method with minor changes (Smith et al. 1997). Those score indexes were graded as follows semi-quantitatively: no injury = score of 0, injury in 25% of the field = score of 1 (slight), injury in 50% of the field = score of 2 (medium), injury in 75% of the field = score of 3 (medium-severe) and injury throughout the field = score of 4 (severe). Each sample was investigated in five microscopic fields and by scoring of inflammatory cells and goblet cells, and the severity of lung injury was evaluated by the average score.

Statistical analysis

Statistical evaluation of the data obtained at the end of the study was made by using the IBM SPSS Statistics 23 package program, and $p < 0.05$ value was considered statistically significant. The Kruskal–Wallis test was used to determine the difference between groups, which was obtained semi-quantitatively. The determination of different groups was determined by the Mann–Whitney U test. Statistical significance was considered at a p value of < 0.05 . One-way ANOVA (Tukey) and SPSS (version 12.0; SPSS, Chicago, IL) statistics program were used for biochemical analysis. While all values are given as mean $\pm$ standard error of the mean (SEM), results at a p value < 0.05 were considered significant.

Results

Tyrosol treatment showed a regulatory effect on antioxidant parameters

Within the scope of the study, to determine the effects of tyrosol administration on antioxidant parameters in experimental asthma animal model, MDA and GSH levels in lung tissue and GPx and CAT enzyme activities were determined. According to the results, it was observed that the MDA level increased significantly in the OVA group compared to the other groups. On the other hand, it was observed that tyrosol treatment reduced the MDA level to levels close to the control group. Compared to the control group, it reduced the MDA level to lower levels in the Dexamethasone-administered group. When the MDA levels among the groups were compared, there was no statistical difference between the control and OVA + tyrosol groups, but it was significantly higher in the OVA group ($p < 0.001$). When GSH levels were compared among the groups, a significant decrease was observed in the OVA group compared to the control group. On the other hand, the decrease in OVA-oriented GSH level was significantly prevented in the group in which OVA and tyrosol were applied ($p < 0.001$). This effect of tyrosol was slightly greater than that of the group which was administered Dexamethasone. When evaluated in terms of GPx enzyme activities, it was observed that the enzyme activity decreased significantly in the OVA group compared to the control group. On the other hand, it was determined that tyrosol treatment significantly increased the GPx enzyme activity compared to the OVA group ($p < 0.001$). Except for the OVA group, there was no significant difference among the other groups in terms of GPx enzyme activity ($p < 0.001$). When the lung tissue CAT enzyme activities were compared among the groups, there was no statistically significant difference ($p < 0.05$). The effect of tyrosol on antioxidant parameters is given in Table 1.

The effect of tyrosol treatment on IgE, IFN- γ , IL-5, IL-10 and IL-13 levels

IgE, IFN- γ , IL-5, IL-10 and IL-13 cytokine levels were analysed in serum and lung tissue samples in all groups. According to the results, a significant increase was observed in the IgE level in both serum and lung samples in the OVA group compared to the control group. On the other hand, it was determined that IgE levels were significantly decreased in the group where OVA and tyrosol were administered together, in both serum and lung tissues compared to the OVA group. Similar effects were

Table 1 Effects of tyrosol treatment on antioxidant parameters in lung tissue

Group/parameter	MDA (nmol/ml)	GSH (nmol/ml)	GPx (U/g protein)	CAT (U/ml)
Control	4.227 ± 0.34 ^b	4.825 ± 0.12 ^c	176.271 ± 2.70 ^b	35.458 ± 2.05
OVA	7.391 ± 0.34 ^c	2.940 ± 0.23 ^a	148.496 ± 3.66 ^a	34.463 ± 1.21
OVA + Dexa	2.845 ± 0.25 ^a	3.978 ± 0.14 ^b	174.420 ± 2.77 ^b	32.337 ± 1.40
OVA + tyrosol	5.267 ± 0.30 ^b	4.106 ± 0.09 ^b	171.889 ± 1.34 ^b	31.742 ± 1.77
<i>p</i> value	0.000	0.000	0.000	0.355

Values are expressed as mean ± SEM of eight rats in each group. The difference between values with different letters (a, b, c) in the same column is statistically significant

MDA malondialdehyde, GSH reduced glutathione, GPx glutathione peroxidase, CAT catalase

seen in the group treated with Dexa. It was observed that there was no statistically significant difference in IgE levels between the control group and in the groups where tyrosol and Dexa were administered together ($p < 0.01$). When the IFN- γ level was examined in serum and lung tissue samples, a significant increase was observed in both tissues in the OVA group compared to the control group ($p < 0.01$ and $p < 0.001$, respectively). The IFN- γ level in the OVA + tyrosol group in both serum and lung tissue was found to be close to the control group values. When the effects of tyrosol and Dexa were compared, no statistically significant difference was observed in serum and lung tissues ($p < 0.01$ and $p < 0.001$, respectively). When IL-5 levels were examined, it was determined that there was a significant increase in serum and lung samples of the OVA group. It was found that OVA-induced increase was prevented in both tissues in the groups where tyrosol and Dexa were administered. IL-5 levels in both serum and lung tissue in these groups were found to be close to the control group ($p < 0.001$). When IL-10 levels were examined within the scope of the study, a statistically significant increase was observed in the groups who underwent tyrosol and Dexa treatment compared to the OVA group ($p < 0.05$). On the other hand, when the lung tissues were examined, it was seen that the IL-10 level in the OVA group decreased slightly, although not statistically significant. It was determined that the tyrosol treatment significantly increased the IL-10 level compared to the OVA group. When the OVA and Dexa groups were compared,

it was found that the IL-10 level increased significantly in the Dexa group ($p < 0.001$). When IL-13 levels were examined in serum and lung tissue samples, it was determined that there was a significant increase in the OVA group compared to the control group, and that tyrosol treatment prevented this increase significantly ($p < 0.01$ and $p < 0.001$, respectively). While the IL-13 level in the group who underwent tyrosol in serum tissue was found to be close to that in the control group ($p < 0.01$), this difference was statistically significant in lung tissue ($p = 0.001$). The effect of Dexa was similar to tyrosol in tissues. The effects of tyrosol treatment on IgE, IFN- γ , IL-5, IL-10 and IL-13 levels for serum and lung tissues are summarized in Tables 2 and 3, respectively.

Effect of tyrosol treatment on TNF- α , IL-1 β , IL-4 and NF- κ B levels

TNF- α , IL-1 β , IL-4 and NF- κ B levels of serum and lung tissue were examined. Accordingly, while a significant increase in the level of TNF- α was observed in both tissues in the OVA group, it was determined that tyrosol significantly prevented this increase ($p < 0.01$). When the tyrosol and Dexa groups were compared, it was observed that TNF- α levels were not statistically significant ($p > 0.01$). When serum and lung tissue IL-1 β levels were analysed, no statistically significant difference was observed among the groups ($p > 0.05$). When the IL-4 level was examined, no statistically significant difference was found among the groups in serum

Table 2 The effects of tyrosol treatment on IgE, IFN- γ , IL-5, IL-10 and IL-13 levels in serum

Group/parameter	IgE (pg/ml)	IFN- γ (pg/ml)	IL-5 (pg/ml)	IL-10 (pg/ml)	IL-13 (pg/ml)
Control	10.840 ± 0.54 ^a	30.792 ± 1.39 ^a	8.072 ± 0.20 ^a	98.015 ± 3.67 ^{a,b}	15.061 ± 0.37 ^a
OVA	13.325 ± 0.19 ^b	37.025 ± 0.33 ^b	9.675 ± 0.12 ^b	94.717 ± 1.49 ^a	18.082 ± 0.51 ^b
OVA + Dexa	11.317 ± 0.29 ^a	31.794 ± 0.98 ^a	8.252 ± 0.15 ^a	107.909 ± 4.15 ^b	15.821 ± 0.44 ^a
OVA + tyrosol	11.765 ± 0.20 ^a	31.868 ± 0.99 ^a	8.335 ± 0.29 ^a	104.795 ± 1.54 ^b	16.067 ± 0.40 ^a
<i>p</i> value	0.001	0.002	0.000	0.024	0.001

Values are expressed as mean ± SEM of eight rats in each group. The difference between values with different letters (a, b, c) in the same column is statistically significant

IgE immunoglobulin E, IFN- γ interferon gamma, IL interleukin

samples ($p > 0.05$). On the other hand, it was determined that the IL-4 level of the lung tissue increased significantly in the OVA group compared to the control group, and that this increase was significantly prevented in the tyrosol treatment group ($p < 0.01$). IL-4 levels were similar in tyrosol, Dexa and control groups. When the serum NF- κ B level was examined, a statistically significant increase was found in the OVA group compared to the control group ($p < 0.01$). Although some decrease in NF- κ B level was observed in the groups treated with tyrosol, it was not statistically significant compared to the OVA group. The effect of Dexa and tyrosol on the level of NF- κ B was similar. When the lung tissue NF- κ B levels were compared among the groups, it was seen that the NF- κ B level in the OVA group was significantly higher than the other groups. However, NF- κ B levels decreased significantly in the tyrosol and Dexa treatment groups compared to the OVA group. NF- κ B levels of control, tyrosol and Dexa groups were close to each other. The

effects of tyrosol on TNF- α , IL-1 β , IL-4 and NF- κ B levels are summarized in Tables 4 and 5, respectively.

Effects of tyrosol treatment on inflammatory cell numbers

Within the scope of the study, the neutrophil, eosinophil, lymphocyte and monocyte percentage counts were found in blood and BALF samples. According to the data obtained, it was determined that the percentage neutrophil count was not statistically significant among the groups in BALF ($p > 0.05$). As for the blood tissue neutrophil count value in percent, while a significant increase was seen in the group who underwent Dexa, no significant difference was observed among the other groups ($p < 0.001$). When the percentage of eosinophils in blood samples was examined, a significant increase was seen in the OVA group compared to the control group. On the other hand, this value decreased in the tyrosol

Table 3 The effects of tyrosol treatment on IgE, IFN- γ , IL-5, IL-10 and IL-13 levels in lung tissue

Group/parameter	IgE (pg/ml)	IFN- γ (pg/ml)	IL-5 (pg/ml)	IL-10 (pg/ml)	IL-13 (pg/ml)
Control	16.592 $\pm$ 0.44 ^a	30.145 $\pm$ 1.40 ^a	9.207 $\pm$ 0.51 ^a	91.015 $\pm$ 2.37 ^a	14.771 $\pm$ 0.21 ^a
OVA	20.799 $\pm$ 0.82 ^b	44.647 $\pm$ 2.22 ^b	13.361 $\pm$ 0.47 ^b	83.059 $\pm$ 2.31 ^a	20.316 $\pm$ 0.80 ^c
OVA + Dexa	15.615 $\pm$ 0.64 ^a	33.907 $\pm$ 1.03 ^a	9.893 $\pm$ 0.20 ^a	122.317 $\pm$ 3.80 ^c	16.714 $\pm$ 0.12 ^b
OVA + tyrosol	15.627 $\pm$ 1.42 ^a	30.917 $\pm$ 1.30 ^a	9.314 $\pm$ 0.30 ^a	104.537 $\pm$ 1.84 ^b	16.969 $\pm$ 0.29 ^b
<i>p</i> value	0.003	0.000	0.000	0.000	0.000

Values are expressed as mean $\pm$ SEM of eight rats in each group. The difference between values with different letters (a, b, c) in the same column is statistically significant

Table 4 The effects of tyrosol treatment on TNF- α , IL-1 β , IL-4 and NF- κ B levels in serum

Group/parameter	TNF- α (pg/ml)	IL-1 β (pg/ml)	IL-4 (pg/ml)	NF- κ B (pg/ml)
Control	133.383 $\pm$ 2.12 ^a	916.100 $\pm$ 71.45	52.498 $\pm$ 1.54	2.283 $\pm$ 0.448 ^a
OVA	149.372 $\pm$ 3.72 ^b	912.567 $\pm$ 49.35	57.574 $\pm$ 1.58	3.762 $\pm$ 0.14 ^b
OVA + Dexa	134.248 $\pm$ 1.65 ^a	931.000 $\pm$ 47.62	52.211 $\pm$ 2.15	2.869 $\pm$ 0.09 ^{ab}
OVA + tyrosol	138.713 $\pm$ 0.95 ^a	908.500 $\pm$ 29.563	52.440 $\pm$ 0.56	2.802 $\pm$ 0.21 ^{ab}
<i>p</i> value	0.001	0.990	0.077	0.009

Values are expressed as mean $\pm$ SEM of eight rats in each group. The difference between values with different letters (a, b) in the same column is statistically significant

TNF- α tumour necrosis factor alpha, IL-1 β interleukin-1 beta, IL-4 interleukin-4, NF- κ B nuclear factor kappa-light-chain-enhancer of activated B cells

Table 5 The effects of tyrosol treatment on TNF- α , IL-1 β , IL-4 and NF- κ B levels in lung tissue

Group/parameter	TNF- α (pg/ml)	IL-1 β (pg/ml)	IL-4 (pg/ml)	NF- κ B (pg/ml)
Control	120.551 $\pm$ 9.28 ^a	842.766 $\pm$ 33.42	52.371 $\pm$ 1.18 ^a	2.697 $\pm$ 0.12 ^a
OVA	151.729 $\pm$ 9.57 ^b	880.200 $\pm$ 31.74	74.983 $\pm$ 5.07 ^b	3.390 $\pm$ 0.14 ^b
OVA + Dexa	108.248 $\pm$ 4.88 ^a	920.900 $\pm$ 64.49	51.696 $\pm$ 1.54 ^a	2.771 $\pm$ 0.27 ^a
OVA + tyrosol	127.227 $\pm$ 2.02 ^a	842.899 $\pm$ 41.52	53.303 $\pm$ 4.52 ^a	2.666 $\pm$ 0.16 ^a
<i>p</i> value	0.004	0.570	0.001	0.045

Values are expressed as mean $\pm$ SEM of eight rats in each group. The difference between values with different letters (a, b, c) in the same column is statistically significant

group almost to the same level as the control group. The reducing effect of tyrosol on the percentage eosinophil count was statistically significantly higher than Dexa ($p < 0.001$). When the percentage of eosinophils in BALF was examined, it was figured out that there was a statistically significant difference among all groups. Accordingly, an increase was observed in the OVA group compared to the control group. It was determined that the percentage of eosinophils decreased significantly in the groups who underwent tyrosol and Dexa compared to the OVA group. When these groups were compared among themselves, it was seen that the percentage of eosinophils in the Dexa group was lower than that of the tyrosol group ($p < 0.001$). When the percentage lymphocyte counts were examined, it was found that there was no significant difference in blood tissue between the control, OVA and tyrosol groups. However, this value was found to be significantly decreased in the Dexa group compared to the other groups. When the BALF percentage lymphocyte counts were examined among the groups, it was seen that there was a significant decrease in the OVA group. It was seen that the tyrosol treatment eliminated this effect and brought the percent lymphocyte levels to similar levels with the control group. It was observed that the percentage of lymphocytes increased in the Dexa group compared to the control group ($p < 0.001$). When blood tissue percentage monocyte values were examined, there was no significant difference among the OVA group, the control and tyrosol groups. When the Dexa and OVA groups were compared, this value was found to be significantly higher in the Dexa group ($p < 0.05$). When the BALF percent monocyte counts were examined, there was a statistically significant decrease in the other groups

compared to the control group ($p < 0.001$). It was observed that tyrosol and Dexa treatments had no effect on percent monocyte values. The obtained data are given in Tables 6 and 7.

Histopathological evaluation

The H&E and PAS staining findings of histopathological sections of rat pulmonary tissues in each group, inflammation scores, MPS and histopathological findings are shown in Fig. 1, Fig. 2, Fig. 3, Fig. 4 and Table 8, respectively. To determine the histological features of lung tissue, H&E and PAS staining were performed. There were statistically significant differences between groups in terms of inflammation score and MPS ($p < 0.0001$). The inflammation score was 0.250 ± 0.16 in the control group, 3.125 ± 0.227 in the OVA group, 1.375 ± 0.183 in the OVA + tyrosol group and 1.125 ± 0.227 in the OVA + Dexa group. MPS was 0.250 ± 0.16 in the control group, 3.250 ± 0.250 in the OVA group, 1.250 ± 0.16 in the OVA + tyrosol group and 1.000 ± 0.189 in the OVA + Dexa group. Microscopical examination of H&E sections from the rats of the control group showed the normal histological structure (Fig. 1). The marked typical pathological features were observed in the OVA-induced group as compared to the control group. From moderate to severe alveolar and bronchiolar damage with thickened interalveolar septa, massive inflammatory cell infiltrations, perivascular and peribronchiolar oedema, haemorrhage, emphysema of some alveoli and vascular congestion were observed in histology of lung tissue from OVA-induced rats. Proliferation (epithelialization)

Table 6 The effect of tyrosol treatment on blood leukocyte counts (%)

Group/parameter	Neutrophil	Eosinophil	Lymphocyte	Monocyte
Control	19.500 ± 1.25^a	2.000 ± 0.36^a	72.333 ± 1.28^b	6.166 ± 0.70^{ab}
OVA	18.666 ± 0.80^a	8.833 ± 0.70^c	67.166 ± 0.87^b	5.166 ± 0.47^a
OVA + Dexa	67.000 ± 2.08^b	4.166 ± 0.30^b	20.000 ± 2.11^a	8.833 ± 1.24^b
OVA + tyrosol	21.166 ± 1.44^a	1.833 ± 0.30^a	71.166 ± 1.30^b	5.833 ± 0.65^{ab}
<i>p</i> value	0.000	0.000	0.000	0.026


Values are expressed as mean $\pm$ SEM of eight rats in each group. The difference between values with different letters (a, b, c) in the same column is statistically significant

Table 7 The effect of tyrosol treatment on BALF leukocyte counts (%)

Group/parameter	Neutrophil	Eosinophil	Lymphocyte	Monocyte
Control	0.500 ± 0.22	0.333 ± 0.21^a	7.166 ± 0.70^b	92.000 ± 0.81^b
OVA	1.166 ± 0.30	7.166 ± 0.40^d	4.833 ± 0.30^a	86.833 ± 0.79^a
OVA + Dexa	0.833 ± 0.40	2.666 ± 0.33^b	9.166 ± 0.30^c	87.500 ± 0.42^a
OVA + tyrosol	0.833 ± 0.30	5.000 ± 0.36^c	7.833 ± 0.47^{bc}	86.666 ± 0.66^a
<i>p</i> value	0.540	0.000	0.000	0.000

Values are expressed as mean $\pm$ SEM of eight rats in each group. The difference between values with different letters (a, b, c) in the same column is statistically significant

Fig. 1 Representative histological changes of the lung obtained from rats of different groups. (H&E). **A** Control: normal histological appearance of the lung tissues of rats. **B–D** OVA: the appearance of moderate to severe histopathological lesions in the lung tissues of rats. **E** OVA + tyrosol: the appearance of minimal lesions in the lung tissues of rats. **F** OVA + Dexa: the appearance of minimal lesions in the lung tissues of rats. (Interalveolar septum enlargement (bidirectional arrow), oedema (e), congestion (c), perivascularitis (pv), peribronchiolitis (pr), inflammatory cell infiltration in bronchiolar propria mucosa (arrow), follicular lymphoid cell hyperplasia (h), emphysema in the alveoli (em), epithelialized areas (asterisk), proliferation (epithelialization) in type II epithelial cells (arrowhead), haemorrhage (he))




was detected in type II epithelial cells in some alveoli. In addition, inflammatory cell infiltration situated locally in bronchial and bronchiolar propria mucosa and lymphoid cell hyperplasia in the manner of peribronchiolar follicle was noted (Fig. 1). Treatment with tyrosol and Dexa markedly reduced pulmonary injury. Lung tissues from tyrosol (Fig. 1) and Dexa (Fig. 1) group rats showed slight infiltration of inflammatory cells. In these groups, mild enlargement of the interalveolar septa and rarely peribronchiolar lymphoid cell hyperplasia were seen. In the histopathological examinations of the sections stained with PAS, no increase in goblet cells and mucus secretion was found in the control group (Fig. 2). The lung tissue of OVA-induced rats showed mucus hypersecretion and goblet cell hyperplasia (Fig. 2). However, co-treatment with tyrosol (Fig. 2) and Dexa (Fig. 2) gave rise to a reduction of goblet cell hyperplasia and mucus overproduction in the lung tissue.

Discussion

Asthma, one of the most common chronic and non-communicable diseases, causes disruptions in quality of life and lifestyle, and it is a burden on families, communities and countries (Pérez et al. 2020). It has been reported that asthma is difficult to treat due to the complexity of its aetiology, and that elucidation of the underlying mechanisms is of great importance in order to develop highly effective drugs with low side effects (Ma et al. 2019). The OVA-induced airway inflammation model has many similarities with human allergic asthma symptoms (Maslan and Mims 2014). In the study, the protective effects of tyrosol in the OVA-induced asthma model were examined. In this context, tyrosol was given to rats together with OVA and Dexa was given to another group to compare the efficacy of tyrosol. At the end of the experimental application, biochemical and histopathological examinations were performed on

Fig. 2 Representative of mucus secretions (arrows) in the PAS-stained sections of lung obtained from rats of different groups. **A** Control, **B** OVA, **C** OVA + tyrosol and **D** OVA + Dexa groups



serum, blood, BALF and lung tissue. The effects of tyrosol on antioxidant parameters, IgE, inflammation markers, inflammation cell numbers and histopathological changes were examined in the samples.

It has been stated in previous studies that the airways of asthmatic patients are stimulated in a manner to cause excessive oxidative stress, and that this increased mucus and sputum production and also damaged lung cells (Susan et al. 2015). One of the formation mechanisms of MDA is lipid peroxidation which is induced by oxygen radicals. Lipid peroxidation causes a decrease in membrane fluidity and impairment of membrane function (Kuzu et al. 2019). Formation of MDA is considered as one of the main markers of oxidative stress (Türk et al. 2020). In the study, it was observed that the MDA level increased significantly in the OVA-treated group compared to the control group. It has

been reported that OVA exposure alters redox homeostasis and reduces antioxidant defence mechanism, resulting in induction of the production of highly reactive hydroxyl radicals, stimulation of lipid peroxidation and cellular damage (Tiwari et al. 2014). However, it was figured out that MDA in the tyrosol-treated group decreased to the levels of the control group. In the study conducted by Güvenç et al. (2020), it was reported that MDA increased in rats treated with AlCl_3 , whereas tyrosol treatment significantly decreased the MDA level. GSH is an important cellular antioxidant that prevents the redox cycle and free radical formation (Martínez-Martos et al. 2014). In general, the increase in reactive oxygen species can be expressed by a decrease in the GSH level or the GSH/GSSG (oxidized glutathione) ratio (Kuzu et al. 2018). In the study, it was observed that the GSH level decreased significantly in the

Fig. 3 Effects of tyrosol on the inflammation score of pulmonary tissues. $P=0.000$. Data are expressed as mean $\pm$ SEM. Different superscript letters (a, b, c) within the same column show statistically significant differences between the groups. (DEX, dexamethasone)





Fig. 4 Effects of tyrosol on the Mucus Production Scores (MPS) of pulmonary tissues. $P:0.000$ Data are expressed as mean $\pm$ SEM. Different superscript letters (a, b, c) within the same column show statistically significant differences between the groups



OVA group compared to the control group, whereas the GSH level in both the Dexa and tyrosol treatment groups came close to the control group values. This curative effect of tyrosol was slightly higher than that of Dexa. In previous studies, it was reported that OVA exposure caused a decrease in GSH level and that this situation was associated with an increase in their consumption due to lipid peroxidation, and it was found that Dexa treatment prevented this situation (Hanna et al. 2019). The effect of tyrosol on GSH level was investigated in the dextran sulfate sodium-induced colitis model, and its curative effect on decreasing GSH level was reported (Güvenç et al. 2019). GPx has been reported as one of the main antioxidants in the lungs, and its activity has been shown to be reduced in asthma (Rahman et al. 2006). A decrease in GPx levels inhibits the production of Th1-dependent cytokines and increases Th2-related responses (Peterson et al. 1998). Within the scope of the study, when lung GPx activities were compared among the groups, it was seen that GPx activity was significantly decreased in the OVA group compared to the control group, and that the GPx activity in the tyrosol and Dexa treatment groups was similar to the control group. In the diabetes model created experimentally in rats, it has been reported that tyrosol prevents the decrease in GPx enzyme activity in the liver and pancreatic tissue and reduces the formation of free oxygen species thanks to its antioxidant properties (Chandramohan and Pari 2016). It is stated that tyrosol can accumulate in the cell over time and reach useful concentrations to exert its protective effects. Various studies performed before show that biophenols such as tyrosol activate endogenous defence systems and, especially, they preserve intracellular GSH content and activate related enzymes, which are glutathione reductase, glutathione peroxidase and gamma glutamyl-cysteine synthetase, and that they provide an indirect protection against oxidative stress (Di Benedetto et al. 2007). In this study, CAT enzyme activity was examined to specify the effect of tyrosol on antioxidant parameters. However, it was figured out that there was no statistically significant difference among the groups in terms of CAT activity. In previous

studies, it was reported that CAT activity was decreased (Dalouchi et al. 2021) or that no change was observed in OVA-induced experimental animals (Pourmehdi et al. 2020). It is thought that the different results obtained from the studies are due to the different administrations of OVA treatment

Table 8 The effects of tyrosol treatment on lung histopathology

Changes/lesions	Control	OVA	OVA + TYR	OVA + DEX
Thickened interalveolar septa	–/8	8/8	8/8	8/8
Slight	–	–	7	7
Moderate	–	5	1	1
Severe	–	3	–	–
Epithelialization	–/8	8/8	0/8	0/8
Slight	–	1	–	–
Moderate	–	3	–	–
Severe	–	4	–	–
Haemorrhage	0/8	8/8	0/8	0/8
Slight	–	3	–	–
Moderate	–	4	–	–
Severe	–	1	–	–
Lymphoid cell hyperplasia	–/8	8/8	5/8	4/8
Slight	–	–	4	3
Moderate	–	5	1	1
Severe	–	3	–	–
Congestion	0/8	8/8	0/8	0/8
Slight	–	4	–	–
Moderate	–	3	–	–
Severe	–	1	–	–
Goblet cell hyperplasia	–/8	8/8	6/8	5/8
Slight	–	–	5	5
Moderate	–	2	1	–
Severe	–	6	–	–

Data are numbers of rats showing changes/number of rats examined for each treatment group. All groups, $n=8$. No injury = score of 0; injury in 25% of the field = score of 1 (slight); injury in 50% of the field = score of 2 (medium); injury in 75% of the field = score of 3 (medium-severe); and injury throughout the field = score of 4 (severe)

to different experimental animals. It has been reported that OVA exposure alters redox homeostasis and decreases the antioxidant defence mechanism, causing an increase in reactive species, consequentially resulted in lipid peroxidation and cellular damage (Yosri et al. 2017). Considering the effect of tyrosol on antioxidant parameters within the scope of the study, it can be said that it helps to protect the intracellular redox balance and prevents lipid peroxidation by increasing GSH level and GPx activity. In a previous study, tyrosol was reported to have an in vitro radical scavenging effect (Chandramohan et al. 2017). Therefore, it may be said that tyrosol shows its antioxidant effect determined in the study both directly and by supporting the endogenous antioxidant defence system.

IgE, produced by B cells and binding to specific FcεRI receptors found on mast cells, is the main agent released in allergic asthma, and which stimulates the degranulation of these cells and the release of allergic bronchoconstrictive factors including leukotrienes, prostaglandins and histamine (Barnes 2008a). Within the scope of the study, IgE levels were measured in both serum and lung tissue in order to investigate the effect of tyrosol treatment on allergic reactions. According to the results, it was observed that the IgE levels in both serum samples and lung tissues of rats increased in the OVA-induced asthma model compared to the control group, whereas this increase was largely prevented in the groups treated with tyrosol and Dexa. In accordance with this study, it has been stated in previous studies that OVA administration increases the IgE level (Eftekhari et al. 2019). In the study conducted by Je et al. (2015), they reported that tyrosol had a curative effect on IgE levels in mice induced by OVA, and found that this effect was more than Dexa. Lin and colleagues (Lin et al. 2020) stated that OVA exposure increased the IgE level in experimental animals, that the treatment they applied decreased the IgE level and that this effect could occur by suppressing the IL-4 level. It was determined also in our study that IL-4 level decreased with tyrosol treatment. Therefore, it may be said that tyrosol shows its inhibitory effect on IgE by suppressing IL-4 level. Due to the role of IgE in the pathogenesis of asthma, interruption of IgE synthesis or suppression of IgE function by various molecules has been evaluated as a new approach for asthma treatment (Lin et al. 2012). Therefore, tyrosol treatment's prevention of the increase in OVA-induced IgE level becomes important in this respect.

It is known that IFN- γ , a Th1 cytokine, plays a dominant role in many inflammatory diseases and immune disorders (Barnes 2008b). It has been experimentally and clinically proven that changes in IFN- γ levels are associated with the severity and duration of asthma (Rajizadeh et al. 2019). In the conducted study, it was seen that the IFN- γ level in both serum and lung tissue increased in the OVA treatment groups compared to the control group, and that it was

almost the same as the control group in the tyrosol and Dexa treatment groups. In the study conducted by Hanna and colleagues (Hanna et al. 2019), it was observed that the change in IFN- γ level in rats treated with OVA and Dexa was similar to the results obtained from this study. However, in our study, the effect of tyrosol on IFN- γ level was determined for the first time. It has been reported that the NF- κ B signalling pathway is activated to regulate the inflammatory reaction and immune response, which are important pathological features of bronchial asthma (Zhong et al. 2016). Activation of NF- κ B is important for the expression of various inflammatory cytokines, including TNF- α , IL-1 β and IL-4 (Je et al. 2015). It has been reported that while TNF- α and IL-1 β contribute to the inflammatory response and airway constriction, IL-4 plays a role in IgE production and eosinophil growth by B cells. IL-5 affects eosinophil maturation and supports IgE production (Kim et al. 2020). IL-13 contributes to mucus secretion in this process (Nader et al. 2012). In the study, it was determined that NF- κ B and TNF- α levels increased in both serum and lung tissue in the OVA treatment group compared to the control group. On the other hand, in the groups treated with Dexa and tyrosol, NF- κ B in the lung tissue and TNF- α in serum and lung tissues decreased to control group levels. When IL-1 β levels were examined, it was seen that there was no difference among the groups in both tissues. Previous studies have shown that tyrosol decreases NF- κ B activation and alleviates mast cell-mediated allergic inflammation (Je et al. 2015). In another study, it was reported that significant increases in TNF- α level were observed in lung tissue and BALF in experimental animals induced by lipopolysaccharide and that tyrosol treatment caused reductions in both protein level and transcription level of TNF- α in these tissues. In the same study, different from the result we obtained, it was reported that tyrosol decreased the increasing IL-1 β expression (Kim et al. 2017). The difference here is thought to be due to the determination of the amount of IL-1 β at the protein level in our study. The NF- κ B signalling pathway may play an important role in mucus secretion in rats with bronchial asthma. Therefore, it has been emphasized that due to its roles in inflammation and mucus secretion, the NF- κ B signalling pathway may be an effective therapeutic target of bronchial asthma (Liu et al. 2020). In the study, IL-4, IL-5 and IL-13 levels, among Th2 cytokines, were examined in serum and lung tissues. It was figured out that cytokines in serum, except IL-4, increased in OVA treatment groups compared to the control group and all cytokine levels increased in lung tissue compared to the control group. Yan et al. (2011) reported that Th2 cells in the lungs of asthmatic patients secrete large amounts of IL-4, IL-5 and IL-13. However, tyrosol treatment was found to reduce increasing cytokine levels and this effect was similar to Dexa. It has been stated that Dexa, a glucocorticoid drug, exerts its powerful anti-inflammatory effect against

bronchial asthma by inhibiting the production of IL-4, IL-5 and IL-13, which are important cytokines in asthma (Westergaard et al. 2015). However, there is no study investigating the effect of tyrosol on these cytokines in the literature. In a previous study, it was found that carvacrol, which is a phytochemical having a molecular structure similar to that of tyrosol, reduces the levels of IL-4, IL-5 and IL-13 (Ezz-Eldin et al. 2020). Studies have shown that Th2-mediated cytokines such as IL-4, IL-5 and IL-13 play a role in regulating, prolonging and increasing the inflammatory response in asthma (Thakur et al. 2019; Menzella et al. 2020). In another study, it was reported that asthmatic mice lacking the IL-13 receptor had significantly less airway remodelling than mice with wild-type asthma (Chen et al. 2013). According to the results we obtained from the study, it can be said that tyrosol decreased these cytokine levels in the OVA-induced asthma model in rats and that it showed an anti-inflammatory effect and presented a protective effect. As a cytokine with anti-inflammatory properties, IL-10 limits the immune response by inhibiting the production of various cytokines and chemokines (Bolandi et al. 2021). It has been reported that IL-10 can have beneficial effects in controlling airway remodelling and may reduce type 1 collagen synthesis and smooth muscle cell proliferation (Selzman et al. 1998). In the study, it was determined that IL-10 levels in the serum and lung tissues increased significantly in the tyrosol and Dexamethasone treatment groups compared to the OVA group. It has been reported that IL-10 can be a target in asthma treatment due to its anti-inflammatory effect (Mäkelä et al. 2000). Therefore, it is thought that tyrosol can act against the formation of asthma by increasing the level of IL-10. Excessive activation of Th2 cell is considered to be the main factor playing an important role in pathological symptoms in the lung during the development of asthma (Liou et al. 2020). It has been stated that various allergens play a role in the formation of Th1 and Th2-mediated immune response in the underlying pathogenesis of asthma (Thakur et al. 2019). Therefore, when the results obtained from the study are evaluated together, it can be stated that tyrosol may affect the NF- κ B level and Th1/Th2 cytokine levels induced by OVA and prevent the development of asthma in rats.

Th1/Th2 imbalance is associated with changes in total serum IgE and allergen-specific serum IgE levels, airway response and eosinophilia (Guan et al. 2019). It has also been reported that the number of eosinophils in the peripheral blood and bronchial lavage of asthmatic patients is associated with the severity of the disease (Louis et al. 2000). In the study, it was determined that the number of eosinophils in percent increased significantly in both blood and BALF in the OVA treatment group; however, this increase was prevented in the groups treated with Dexamethasone and tyrosol. While this effect was greater in the BALF in the Dexamethasone group, the effect of tyrosol in the blood was greater than that of Dexamethasone.

In a previous study, it was shown to increase the number of eosinophils in both BALF and serum, similar to the findings related to OVA. It has been stated that this situation is related to increased IL-4, IgE and TNF- α production (Parlar and Arslan 2020). In another study, it was reported that vitamin E treatment reduces the level of IgE indirectly by suppressing the production of IL-4, which increases IgE production, and that of IL-5, which plays a role in eosinophil migration (Jiang et al. 2021). Therefore, it can be said that tyrosol treatment shows its effect on the eosinophil count in percent by decreasing the levels of IgE, TNF- α , IL-4 and IL-5.

The histopathological data obtained within the scope of the study support the results obtained from the examination of antioxidant and inflammation markers. Accordingly, it was observed that inflammation and mucus production scores increased in the OVA group compared to the control group and inflammation, congestion, haemorrhage, thickened interalveolar septa, perivascularitis and peribronchiolitis were detected in the lung tissue. It was determined that inflammation and mucus production scores decreased in the groups treated with tyrosol and Dexamethasone and histopathological lesions in the lung tissue were prevented. Previous studies have shown that OVA exposure has caused interstitial inflammation and fibrosis, emphysema and epithelial damage in the lungs of animals and this confirms the induction of sensitivity (Boskabady et al. 2019). In another study, the presence of severe inflammation was shown in histopathological analysis of lung tissue of asthma-induced rats (Zhu et al. 2019). It has been reported that tyrosol exerts its protective effects on cell structure in animals induced by lipopolysaccharide by suppressing inflammatory cell infiltration and pulmonary oedema (Kim et al. 2017). In another study, it was reported that tyrosol can improve the survival rate of mice in acute lung injury induced by lipopolysaccharide and reduce lung damage by suppressing the inflammatory reaction and oxidative stress (Wang et al. 2017). In our study, it is thought that tyrosol contributes to the preservation of tissue architecture with its regulating effect on antioxidant parameters and inflammation-reducing effect.

Conclusion

Asthma is characterized by bronchial inflammation, oxidative stress and an imbalance in antioxidant defence mechanisms. According to the results obtained from the study, it was determined that tyrosol treatment strengthens the antioxidant defence system, reduces allergic response and prevents airway inflammation by regulating pro-inflammatory and anti-inflammatory cytokine levels and by reducing inflammatory cell numbers. Besides, it improves asthma

symptoms in the OVA-induced asthma model. However, the current study contains some limitations. It is considered as necessary to investigate different doses of tyrosol and its effects on the different pathways that cause inflammation. In addition, with new studies to be conducted, it is important to specify the therapeutic properties in rats already with asthma and to investigate potential clinical benefits.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00210-021-02117-y>.

Author contribution MC conceived and designed the research. MK, CTİ, ME, ND, AU, İG, ET and MG conducted the experiments. MG analysed the data. MK, MC and CTİ wrote the manuscript. All authors read and approved the manuscript. All data were generated in-house, and no paper mill was used.

Funding This research was supported by the Unit of Scientific Research Projects of Mustafa Kemal University (Project number 19.M.041).

Data availability All data generated or analysed during this study are included in this published article (and its [supplementary information files](#)).

Declarations

Ethics approval and consent to participate All applications within the scope of the experiment were carried out within the framework of the permit of Hatay Mustafa Kemal University Animal Experiments Local Ethics Committee, numbered 2019/09–3. Consent to participate is not applicable.

Consent for publication Not applicable.

Conflict of interest The authors declare no competing interests.

References

- Aebi H (1984) Catalase in vitro. *Methods Enzymol* 105:121–126. [https://doi.org/10.1016/S0076-6879\(84\)05016-3](https://doi.org/10.1016/S0076-6879(84)05016-3)
- Atochin DN, Chernysheva GA, Smolyakova VI et al (2016) Neuroprotective effects of p-tyrosol after the global cerebral ischemia in rats. *Phytomedicine* 23:784–792. <https://doi.org/10.1016/j.phymed.2016.03.015>
- Barnes PJ (2008a) Immunology of asthma and chronic obstructive pulmonary disease. *Nat Rev Immunol* 8:183–192. <https://doi.org/10.1038/nri2254>
- Barnes PJ (2008b) The cytokine network in asthma and chronic obstructive pulmonary disease. *J Clin Invest* 118:3546–3556. <https://doi.org/10.1172/JCI36130>
- Beutler E (1975) Red cell metabolism. In: *A manual of biochemical methods*. Grune Strottan, New York
- Beutler E, Dubon O, Kelly B (1963) Improved method for the determination of blood glutathione. *J Lab Clin Med* 61:882–888
- Bolandi SM, Abdolmaleki Z, Assarehzadegan M-A (2021) Bevacizumab regulates inflammatory cytokines and inhibits VEGFR2 signaling pathway in an ovalbumin-induced rat model of airway hypersensitivity. *Inflammopharmacology* 1:3. <https://doi.org/10.1007/s10787-021-00798-8>
- Boskabady MH, Kaveh M, Shakeri F et al (2019) Alpha-linolenic acid ameliorates bronchial asthma features in ovalbumin-sensitized rats. *J Pharm Pharmacol* 71:1089–1099. <https://doi.org/10.1111/jphp.13094>
- Bu Y, Rho S, Kim J et al (2007) Neuroprotective effect of tyrosol on transient focal cerebral ischemia in rats. *Neurosci Lett* 414:218–221. <https://doi.org/10.1016/j.neulet.2006.08.094>
- Chan CK, Lin TC, Huang YA et al (2016) The modulation of Th2 immune pathway in the immunosuppressive effect of human umbilical cord mesenchymal stem cells in a murine asthmatic model. *Inflamm Res* 65:795–801. <https://doi.org/10.1007/s00011-016-0961-y>
- Chandramohan R, Pari L (2016) Anti-inflammatory effects of tyrosol in streptozotocin-induced diabetic Wistar rats. *J Funct Foods* 27:17–28. <https://doi.org/10.1016/j.jff.2016.08.043>
- Chandramohan R, Pari L, Rathinam A, Sheikh BA (2015) Tyrosol, a phenolic compound, ameliorates hyperglycemia by regulating key enzymes of carbohydrate metabolism in streptozotocin induced diabetic rats. *Chem Biol Interact* 229:44–54. <https://doi.org/10.1016/j.cbi.2015.01.026>
- Chandramohan R, Saravanan S, Pari L (2017) Beneficial effects of tyrosol on altered glycoprotein components in streptozotocin-induced diabetic rats. *Pharm Biol* 55:1631–1637. <https://doi.org/10.1080/13880209.2017.1315603>
- Chen W, Sivaprasad U, Gibson AM et al (2013) IL-13 receptor $\alpha 2$ contributes to development of experimental allergic asthma. *J Allergy Clin Immunol* 132:951–958.e6. <https://doi.org/10.1016/j.jaci.2013.04.016>
- Chiappara G, Gagliardo R, Siena A et al (2001) Airway remodelling in the pathogenesis of asthma. *Curr Opin Allergy Clin Immunol* 1:85–93
- Dalouchi F, Falak R, Bakhshesh M et al (2021) Human amniotic membrane mesenchymal stem cell-conditioned medium reduces inflammatory factors and fibrosis in ovalbumin-induced asthma in mice. *Exp Physiol* 106:544–554. <https://doi.org/10.1113/EP088911>
- Di Benedetto R, Vari R, Scazzocchio B et al (2007) Tyrosol, the major extra virgin olive oil compound, restored intracellular antioxidant defences in spite of its weak antioxidative effectiveness. *Nutr Metab Cardiovasc Dis* 17:535–545. <https://doi.org/10.1016/j.numecd.2006.03.005>
- Eftekhari N, Moghimi A, Mohammadian Roshan N et al (2019) Immunomodulatory and anti-inflammatory effects of hydro-ethanolic extract of *Ocimum basilicum* leaves and its effect on lung pathological changes in an ovalbumin-induced rat model of asthma. *BMC Complement Altern Med* 19:349. <https://doi.org/10.1186/s12906-019-2765-4>
- Elaidy SM, Essawy SS, Hussain MA et al (2018) Modulation of the IL-23/IL-17 axis by fenofibrate ameliorates the ovalbumin/lipopolysaccharide-induced airway inflammation and bronchial asthma in rats. *Naunyn Schmiedeberg's Arch Pharmacol* 391:309–321. <https://doi.org/10.1007/s00210-017-1459-z>
- Ezz-Eldin YM, Aboseif AA, Khalaf MM (2020) Potential anti-inflammatory and immunomodulatory effects of carvacrol against ovalbumin-induced asthma in rats. *Life Sci* 242:117222. <https://doi.org/10.1016/j.lfs.2019.117222>
- Fitó M, Covas MI, Lamuela-Raventós RM et al (2000) Protective effect of olive oil and its phenolic compounds against low density lipoprotein oxidation. *Lipids* 35:633–638. <https://doi.org/10.1007/s11745-000-0567-1>
- Guan Y, Shen HJ, Shen J et al (2019) Anti-allergic activities of 5,7-dimethoxy-3,4'-dihydroxyflavone via inhalation in rat allergic models. *Eur J Pharmacol* 848:55–61. <https://doi.org/10.1016/j.ejphar.2019.01.046>

- Güvenç M, Cellat M, Gökçek İ et al (2020) Tyrosol prevents AlCl_3 induced male reproductive damage by suppressing apoptosis and activating the Nrf-2/HO-1 pathway. *Andrologia* 52:e13499. <https://doi.org/10.1111/and.13499>
- Güvenç M, Cellat M, Özkan H et al (2019) Protective effects of tyrosol against DSS-induced ulcerative colitis in rats. *Inflammation* 42:1680–1691. <https://doi.org/10.1007/s10753-019-01028-8>
- Hanna DA, Khalaf MM, Abo-Saif AA (2019) Polydatin protects against ovalbumin-induced bronchial asthma in rats; involvement of urocortin and surfactant-D expression. *Immunopharmacol Immunotoxicol* 41:403–412. <https://doi.org/10.1080/08923973.2018.1536985>
- Innes Asher M, García-Marcos L, Pearce NE, Strachan DP (2020) Trends in worldwide asthma prevalence. *Eur Respir J* 56. <https://doi.org/10.1183/13993003.02094-2020>
- Irwin RS, Richardson ND (2006) Side effects with inhaled corticosteroids: the physician's perception. *Chest* 130:41–53. https://doi.org/10.1378/chest.130.1_suppl.41S
- Je I-G, Kim D-S, Kim S-W et al (2015) Tyrosol suppresses allergic inflammation by inhibiting the activation of phosphoinositide 3-kinase in mast cells. *PLoS One* 10:e0129829. <https://doi.org/10.1371/journal.pone.0129829>
- Jiang J, Mehrabi Nasab E, Athari SM, Athari SS (2021) Effects of vitamin E and selenium on allergic rhinitis and asthma pathophysiology. *Respir Physiol Neurobiol* 286:103614. <https://doi.org/10.1016/j.resp.2020.103614>
- Kaplan A, Mitchell PD, Cave AJ et al (2020) Effective asthma management: is it time to let the AIR out of SABA? *J Clin Med* 9:921. <https://doi.org/10.3390/jcm9040921>
- Kim YY, Hur G, Lee SW et al (2020) AGK2 ameliorates mast cell-mediated allergic airway inflammation and fibrosis by inhibiting FcεRI/TGF-β signaling pathway. *Pharmacol Res* 159:105027. <https://doi.org/10.1016/j.phrs.2020.105027>
- Kim YY, Lee S, Kim MJ et al (2017) Tyrosol attenuates lipopolysaccharide-induced acute lung injury by inhibiting the inflammatory response and maintaining the alveolar capillary barrier. *Food Chem Toxicol* 109:526–533. <https://doi.org/10.1016/j.fct.2017.09.053>
- Kuzu M, Kandemir FM, Yildirim S et al (2018) Morin attenuates doxorubicin-induced heart and brain damage by reducing oxidative stress, inflammation and apoptosis. *Biomed Pharmacother* 106:443–453. <https://doi.org/10.1016/j.biopha.2018.06.161>
- Kuzu M, Yildirim S, Kandemir FM et al (2019) Protective effect of morin on doxorubicin-induced hepatorenal toxicity in rats. *Chem Biol Interact* 308:89–100. <https://doi.org/10.1016/j.cbi.2019.05.017>
- Lin LJ, Lin CC, Wang S Der, et al (2012) The immunomodulatory effect of You-Gui-Wan on Dermatogoides-pteronyssinus-induced asthma. *Evidence-based Complement Altern Med* 2012. <https://doi.org/10.1155/2012/476060>
- Lin LJ, Wu CJ, Der WS, Te KS (2020) Qi-Wei-Du-Qi-Wan and its major constituents exert an anti-asthmatic effect by inhibiting mast cell degranulation. *J Ethnopharmacol* 254:112406. <https://doi.org/10.1016/j.jep.2019.112406>
- Liou C-J, Chen Y-L, Yu M-C et al (2020) Sesamol alleviates airway hyperresponsiveness and oxidative stress in asthmatic mice. *Antioxidants* 9:295. <https://doi.org/10.3390/antiox9040295>
- Liu Y, Zhang B, Zhang T et al (2020) Effect of NF-κB signal pathway on mucus secretion induced by atmospheric PM_{2.5} in asthmatic rats. *Ecotoxicol Environ Saf* 190:110094. <https://doi.org/10.1016/j.ecoenv.2019.110094>
- Louis R, Lau LCK, Bron AO et al (2000) The relationship between airways inflammation and asthma severity. *Am J Respir Crit Care Med* 161:9–16. <https://doi.org/10.1164/ajrccm.161.1.9802048>
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with pholin phenol reagent. *J Biol Chem* 193:265–275
- Ma C, Zou L, Xia Y et al (2019) Extracts of *Coleus forskohlii* relieves cough and asthma symptoms via modulating inflammation and the extracellular matrix. *J Cell Biochem* 120:9648–9655. <https://doi.org/10.1002/jcb.28243>
- Mäkelä MJ, Kanehiro A, Borish L et al (2000) IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. *Proc Natl Acad Sci U S A* 97:6007–6012. <https://doi.org/10.1073/pnas.100118997>
- Martínez-Martos JM, Mayas MD, Carrera P et al (2014) Phenolic compounds oleuropein and hydroxytyrosol exert differential effects on glioma development via antioxidant defense systems. *J Funct Foods* 11:221–234. <https://doi.org/10.1016/j.jff.2014.09.006>
- Maslan J, Mims JW (2014) What is asthma? Pathophysiology, demographics, and health care costs. *Otolaryngol Clin North Am* 47:13–22. <https://doi.org/10.1016/j.otc.2013.09.010>
- Mattiuzzi C, Lippi G (2020) Worldwide asthma epidemiology: insights from the Global Health Data Exchange database. *Int Forum Allergy Rhinol* 10:75–80. <https://doi.org/10.1002/alr.22464>
- Menzella F, Ruggiero P, Galeone C et al (2020) Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma. *Pulm Pharmacol Ther* 64:101966. <https://doi.org/10.1016/j.pupt.2020.101966>
- Migliorati G, Nicoletti I, Nocentini G et al (1994) Dexamethasone and interleukins modulate apoptosis of murine thymocytes and peripheral T-lymphocytes. *Pharmacol Res* 30:43–52. [https://doi.org/10.1016/1043-6618\(94\)80086-3](https://doi.org/10.1016/1043-6618(94)80086-3)
- Myou S, Leff AR, Myo S et al (2003) Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. *J Exp Med* 198:1573–1582. <https://doi.org/10.1084/jem.20030298>
- Nader MA, El-Awady MS, Shalaby AA, El-Agamy DS (2012) Sitagliptin exerts anti-inflammatory and anti-allergic effects in ovalbumin-induced murine model of allergic airway disease. *Naunyn Schmiedeberg's Arch Pharmacol* 385:909–919. <https://doi.org/10.1007/s00210-012-0772-9>
- Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal Biochem* 95:351–358. [https://doi.org/10.1016/0003-2697\(79\)90738-3](https://doi.org/10.1016/0003-2697(79)90738-3)
- Parlar A, Arslan SO (2020) CB2 agonist (AM1241) improving effect on ovalbumin-induced asthma in rats. *Iran J Pharm Res* 19:3–17. <https://doi.org/10.22037/ijpr.2019.1101002>
- Pérez M, Pérez-Cano FJ, Rodríguez-Lagunas MJ et al (2020) Development and characterization of an allergic asthma rat model for interventional studies. *Int J Mol Sci* 21:3841. <https://doi.org/10.3390/ijms21113841>
- Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C (1998) Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. *Proc Natl Acad Sci U S A* 95:3071–3076. <https://doi.org/10.1073/pnas.95.6.3071>
- Plotnikova MB, Plotnikova TM (2021) Tyrosol as a neuroprotector: strong effects of a “weak” antioxidant. *Curr Neuropharmacol* 19:434–448. <https://doi.org/10.2174/1570159x18666200507082311>
- Pourmehdi A, Sakhaei Z, Alirezai M, Dezfoulian O (2020) Betaine effects against asthma-induced oxidative stress in the liver and kidney of mice. *Mol Biol Rep* 47:5729–5735. <https://doi.org/10.1007/s11033-020-05620-2>
- Rahman I, Biswas SK, Kode A (2006) Oxidant and antioxidant balance in the airways and airway diseases. *Eur J Pharmacol* 533:222–239. <https://doi.org/10.1016/j.ejphar.2005.12.087>
- Rajzadeh MA, Najafipour H, Fekri MS et al (2019) Anti-inflammatory and anti-oxidative effects of myrtenol in the rats with allergic asthma. *Iran J Pharm Res* 18:1488–1498. <https://doi.org/10.22037/ijpr.2019.1100749>
- Regele R (2000) The pathology of asthma: brief review. In: *Immunopharmacology*. Elsevier, pp 257–262

- Rodríguez-Morató J, Boronat A, Kotronoulas A et al (2016) Metabolic disposition and biological significance of simple phenols of dietary origin: hydroxytyrosol and tyrosol. *Drug Metab Rev* 48:218–236. <https://doi.org/10.1080/03602532.2016.1179754>
- Russell RJ, Brightling CE (2017) Pathogenesis of asthma: implications for precision medicine. *Clin Sci* 131:1723–1735
- Saikumar Jayalatha AK, Hesse L, Ketelaar ME et al (2021) The central role of IL-33/IL-1RL1 pathway in asthma: from pathogenesis to intervention. *Pharmacol Ther* 225:107847. <https://doi.org/10.1016/j.pharmthera.2021.107847>
- Selzman CH, McIntyre RC, Shames BD et al (1998) Interleukin-10 inhibits human vascular smooth muscle proliferation. *J Mol Cell Cardiol* 30:889–896. <https://doi.org/10.1006/jmcc.1998.0642>
- Smith K, Mrozek J, Simonton S et al (1997) Prolonged partial liquid ventilation using conventional and high-frequency ventilatory techniques: gas exchange and lung pathology in an animal model of respiratory. *Crit Care Med* 25:1888–1897
- Stern J, Pier J, Litonjua AA (2020) Asthma epidemiology and risk factors. *Semin Immunopathol* 42:5–15
- Sun L-Z, Elsayed S, Aasen TB et al (2010) Comparison between ovalbumin and ovalbumin peptide 323–339 responses in allergic mice: humoral and cellular aspects. *Scand J Immunol* 71:329–335. <https://doi.org/10.1111/j.1365-3083.2010.02382.x>
- Sussan TE, Gajghate S, Chatterjee S et al (2015) Nrf2 reduces allergic asthma in mice through enhanced airway epithelial cytoprotective function. *Am J Physiol Cell Mol Physiol* 309:27–36. <https://doi.org/10.1152/ajplung.00398.2014>
- Tanaka H, Masuda T, Tokuoka S et al (2001) The effect of allergen-induced airway inflammation on airway remodeling in a murine model of allergic asthma. *Inflamm Res* 50:616–624. <https://doi.org/10.1007/PL00000243>
- Thakur VR, Khuman V, Beladiya JV et al (2019) An experimental model of asthma in rats using ovalbumin and lipopolysaccharide allergens. *Heliyon* 5:e02864. <https://doi.org/10.1016/j.heliyon.2019.e02864>
- Tiwari M, Dwivedi UN, Kakkar P (2014) *Tinospora cordifolia* extract modulates COX-2, iNOS, ICAM-1, pro-inflammatory cytokines and redox status in murine model of asthma. *J Ethnopharmacol* 153:326–337. <https://doi.org/10.1016/j.jep.2014.01.031>
- Tuck KL, Hayball PJ (2002) Major phenolic compounds in olive oil: metabolism and health effects. *J Nutr Biochem* 13:636–644. [https://doi.org/10.1016/S0955-2863\(02\)00229-2](https://doi.org/10.1016/S0955-2863(02)00229-2)
- Türk E, Güvenç M, Cellat M, et al (2020) Zingerone protects liver and kidney tissues by preventing oxidative stress, inflammation, and apoptosis in methotrexate-treated rats. *Drug Chem Toxicol* 1–12. <https://doi.org/10.1080/01480545.2020.1804397>
- Wang W, Xia Y, Yang B et al (2017) Protective effects of tyrosol against LPS-induced acute lung injury via inhibiting NF-κB and AP-1 activation and activating the HO-1/Nrf2 pathways. *Biol Pharm Bull* 40:583–593. <https://doi.org/10.1248/bpb.b16-00756>
- Westergaard CG, Porsbjerg C, Backer V (2015) Emerging corticosteroid agonists for the treatment of asthma. *Expert Opin Emerg Drugs* 20:653–662. <https://doi.org/10.1517/14728214.2015.1061503>
- Whitehead GS, Grasman KA, Kimmel EC (2003) Lung function and airway inflammation in rats following exposure to combustion products of carbon-graphite/epoxy composite material: comparison to a rodent model of acute lung injury. *Toxicology* 183:175–197. [https://doi.org/10.1016/S0300-483X\(02\)00542-5](https://doi.org/10.1016/S0300-483X(02)00542-5)
- Yan S, Ci X, Chen N et al (2011) Anti-inflammatory effects of ivermectin in mouse model of allergic asthma. *Inflamm Res* 60:589–596. <https://doi.org/10.1007/s00011-011-0307-8>
- Yang CH, Tian JJ, Ko WS et al (2019) Oligo-fucoidan improved unbalance the Th1/Th2 and Treg/Th17 ratios in asthmatic patients: an ex vivo study. *Exp Ther Med* 17:3–10. <https://doi.org/10.3892/etm.2018.6939>
- Yosri H, Elkashef WF, Said E, Gameil NM (2017) Crocin modulates IL-4/IL-13 signaling and ameliorates experimentally induced allergic airway asthma in a murine model. *Int Immunopharmacol* 50:305–312. <https://doi.org/10.1016/j.intimp.2017.07.012>
- Zhong Z, Umemura A, Sanchez-Lopez E et al (2016) NF-κB restricts inflammasome activation via elimination of damaged mitochondria. *Cell* 164:896–910. <https://doi.org/10.1016/j.cell.2015.12.057>
- Zhu S, Wang H, Zhang J et al (2019) Antiasthmatic activity of quercetin glycosides in neonatal asthmatic rats. *3 Biotech* 9:189. <https://doi.org/10.1007/s13205-019-1618-7>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.